Dennis W. Schneck

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment

Eminy H.Y. Lee, S RYAN, Bruce K. Birmingham et al. · Clinical Pharmacology & Therapeutics · 2005 · 473 citations

Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.

Fergus McTaggart, Linda K. Buckett, Robert G. Davidson et al. · The American Journal of Cardiology · 2001 · 412 citations

Molecular Pharmacology, Medicinal Chemistry, Pharmaceutical Science +12

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

Dennis W. Schneck · Clinical Pharmacology & Therapeutics · 2004 · 293 citations

Pharmacodynamic effects and pharmacokinetics of a new HMG‐CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers

Paul Martin, Pat Mitchell, Dennis W. Schneck · British Journal of Clinical Pharmacology · 2002 · 150 citations · Full text

Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease

Dennis W. Schneck, Robert H. Knopp, Christie M. Ballantyne et al. · The American Journal of Cardiology · 2003 · 139 citations

Hypertension, Cardiovascular Disease, Medicine +9